Table 1 Basic characteristics of included studies
Author | Year | Study type | Nation | Male/female | Age | Hips | Therapies | Evaluation standard | Study quality |
|---|---|---|---|---|---|---|---|---|---|
Gangji | 2011 | RCT | Belgium | 9/10 | 43.86 | 24 | Control: CD Trial: CD+Marrow | Jadad | 6 |
Zhao | 2012 | RCT | China | 53/47 | 33.25 | 97 | Control: CD Trial: CD+Marrow | Jadad | 6 |
Pepke | 2016 | RCT | German | 21/3 | 44.4 | 25 | Control: CD Trial: CD+Marrow | Jadad | 5 |
Zhang HJ | 2010 | Case-control | China | 20/12 | 36.3 | 39 | Control: CD Trial: CD+Marrow | NOS | 8 |
Zhuo NQ | 2012 | Case-control | China | 16/12 | 31.9 | 33 | Control: CD Trial: CD+A.B | NOS | 9 |
Guo HS | 2018 | Case-control | China | 56/20 | 44.32 | 76 | Control: CD Trial: CD+A.B | NOS | 9 |
Warner | 1987 | Case series | USA | 13/12 | 38 | 39 | CD | NICE | 6 |
Tooke | 1988 | Case series | USA | 14/19 | 40 | 45 | CD | NICE | 6 |
Lausten | 1990 | Case series | Denmark | 24/3 | 40 | 29 | CD | NICE | 7 |
Learmonth | 1990 | Case series | South Africa | 21/11 | 37 | 41 | CD | NICE | 5 |
Fairbank | 1994 | Case series | USA | 45/45 | 40 | 128 | CD | NICE | 6 |
Smith | 1995 | Case series | USA | 59/33 | 41 | 114 | CD | NICE | 6 |
Markel | 1996 | Case series | USA | 12/33 | 38.6 | 54 | CD | NICE | 6 |
Mont | 1997 | Case series | USA | 22/28 | 34 | 79 | CD | NICE | 5 |
Powell | 1997 | Case series | USA | 10/12 | 35 | 34 | CD | NICE | 6 |
Iorio | 1998 | Case series | USA | NA | 40.8 | 33 | CD | NICE | 5 |
Bozic | 1999 | Case series | USA | 21/13 | 38 | 54 | CD | NICE | 6 |
Steinberg | 2001 | Case series | USA | 123/85 | 37 | 312 | CD+A.B | NICE | 5 |
Hernigou | 2002 | Case series | USA | 75/41 | 31 | 189 | CD+Marrow | NICE | 6 |
Lieberman | 2004 | Case series | USA | 6/9 | 47 | 17 | CD | NICE | 5 |
Belmar | 2004 | Case series | USA | NA | NA | 302 | CD | NICE | 5 |
Song | 2007 | Case series | South Korea | 120/16 | 36.1 | 163 | CD | NICE | 6 |
Li YP | 2007 | Case series | China | 19/6 | 37.2 | 36 | CD+A.B | NICE | 5 |
Ji WF | 2008 | Case series | China | 71/16 | 47 | 103 | CD+Marrow | NICE | 5 |
Xu WH | 2009 | Case series | China | 26/14 | 35.6 | 42 | CD+A.B | NICE | 5 |
Wang | 2010 | Case series | China | 36/9 | 37.5 | 59 | CD+Marrow | NICE | 5 |
Cao B | 2010 | Case series | China | 37/18 | 39.8 | 61 | CD+A.B | NICE | 5 |
Yang J | 2010 | Case series | China | 50/5 | 35 | 85 | CD | NICE | 5 |
Zhao Y | 2011 | Case series | China | 16/6 | Range (16–51) | 25 | CD | NICE | 6 |
Chotivichit | 2012 | Case series | Thailand | 3/7 | 36.18 | 11 | CD+Marrow | NICE | 6 |
Chotivichit | 2014 | Case series | Thailand | 18/14 | 31.9 | 34 | CD+Marrow | NICE | 6 |
Chen XT | 2015 | Case series | China | 31/19 | 36.2 | 58 | CD+A.B | NICE | 6 |